PURPOSE: To determine the efficacy of imatinib in children with newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML). METHODS: This was an open label, multi-center phase II clinical trial. Courses were defined as consecutive 28-day intervals. Oral imatinib was administered daily at 340 mg/m² without interruption in the absence of toxicity. RESULTS: Fifty-one children received 978 28-day courses of imatinib. The most common toxicities encountered were hematologic. Forty-one patients (80%) achieved a complete hematologic response by the end of course 2. Nineteen children (38%) obtained a complete cytogenetic response (CCyR) at the end of course 3. Overall, 72% achieved CCyR at a median time of 5.6 months. The rate of complete molecular response (>3 log reduction) was 27%. Progression-free and overall survival at 3 years were 72% ± 6.4% and 92% ± 3.9%, respectively. CONCLUSIONS: Daily oral imatinib at a dose of 340 mg/m² is well tolerated in children. In addition, imatinib therapy is effective in inducing a high percent of hematologic, cytogenetic and molecular responses, comparable to adults with CML. (This study was registered at ClinicalTrials.gov under identifier NCT00030394.).
PURPOSE: To determine the efficacy of imatinib in children with newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML). METHODS: This was an open label, multi-center phase II clinical trial. Courses were defined as consecutive 28-day intervals. Oral imatinib was administered daily at 340 mg/m² without interruption in the absence of toxicity. RESULTS: Fifty-one children received 978 28-day courses of imatinib. The most common toxicities encountered were hematologic. Forty-one patients (80%) achieved a complete hematologic response by the end of course 2. Nineteen children (38%) obtained a complete cytogenetic response (CCyR) at the end of course 3. Overall, 72% achieved CCyR at a median time of 5.6 months. The rate of complete molecular response (>3 log reduction) was 27%. Progression-free and overall survival at 3 years were 72% ± 6.4% and 92% ± 3.9%, respectively. CONCLUSIONS: Daily oral imatinib at a dose of 340 mg/m² is well tolerated in children. In addition, imatinib therapy is effective in inducing a high percent of hematologic, cytogenetic and molecular responses, comparable to adults with CML. (This study was registered at ClinicalTrials.gov under identifier NCT00030394.).
Authors: G Dini; R Rondelli; M Miano; J Vossen; E Gluckman; C Peters; P Bordigoni; F Locatelli; R Miniero; P Ljungman; U Saarinen; T Klingebiel; J Ortega; E Lanino Journal: Bone Marrow Transplant Date: 1996-11 Impact factor: 5.483
Authors: Ellin Berman; Maria Nicolaides; Robert G Maki; Martin Fleisher; Suzanne Chanel; Kelly Scheu; Bri-Anne Wilson; Glenn Heller; Nicholas P Sauter Journal: N Engl J Med Date: 2006-05-11 Impact factor: 91.245
Authors: Vivian G Oehler; Ted Gooley; David S Snyder; Laura Johnston; Allen Lin; Carrie C Cummings; Su Chu; Ravi Bhatia; Stephen J Forman; Robert S Negrin; Frederick R Appelbaum; Jerald P Radich Journal: Blood Date: 2006-10-24 Impact factor: 22.113
Authors: Kate Cwynarski; Irene A G Roberts; Simona Iacobelli; Anja van Biezen; Ronald Brand; Agnes Devergie; Jaak M Vossen; Mahmoud Aljurf; William Arcese; Franco Locatelli; Giorgio Dini; Dietrich Niethammer; Dietger Niederwieser; Jane F Apperley Journal: Blood Date: 2003-04-24 Impact factor: 22.113
Authors: S M Davies; T E DeFor; P B McGlave; J S Miller; C M Verfaillie; J E Wagner; D J Weisdorf Journal: Am J Med Date: 2001-04-01 Impact factor: 4.965
Authors: Hagop M Kantarjian; Richard A Larson; Francois Guilhot; Stephen G O'Brien; Manisha Mone; Marc Rudoltz; Tillmann Krahnke; Jorge Cortes; Brian J Druker Journal: Cancer Date: 2009-02-01 Impact factor: 6.860
Authors: Lia Gore; Pamela R Kearns; Maria Lucia de Martino; Carmino Antonio De Souza; Yves Bertrand; Nobuko Hijiya; Linda C Stork; Nack-Gyun Chung; Rocio Cardenas Cardos; Tapan Saikia; Franca Fagioli; Jong Jin Seo; Judith Landman-Parker; Donna Lancaster; Andrew E Place; Karen R Rabin; Mariana Sacchi; Rene Swanink; C Michel Zwaan Journal: J Clin Oncol Date: 2018-03-02 Impact factor: 44.544